First Time Loading...

Madrigal Pharmaceuticals Inc
NASDAQ:MDGL

Watchlist Manager
Madrigal Pharmaceuticals Inc Logo
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Watchlist
Price: 232 USD -0.04% Market Closed
Updated: May 21, 2024

Profitability Summary

Madrigal Pharmaceuticals Inc's profitability score is 43/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

43/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

43/100
Profitability
Score
43/100
Profitability
Score

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Madrigal Pharmaceuticals Inc

Revenue
0 USD
Operating Expenses
-454.2m USD
Operating Income
-454.2m USD
Other Expenses
10m USD
Net Income
-444.2m USD

Margins Comparison
Madrigal Pharmaceuticals Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
4.8B USD N/A N/A
US
Abbvie Inc
NYSE:ABBV
287.1B USD
29%
11%
US
Amgen Inc
NASDAQ:AMGN
167.6B USD
24%
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.1B USD
41%
39%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
109B USD
30%
29%
AU
CSL Ltd
ASX:CSL
134.1B AUD
26%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
83.4B USD
32%
2%
US
Moderna Inc
NASDAQ:MRNA
54.2B USD
-100%
-116%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-33%
-33%
US
Biogen Inc
NASDAQ:BIIB
32.9B USD
22%
12%
KR
Celltrion Inc
KRX:068270
38.6T KRW
30%
25%
Country US
Market Cap 4.8B USD
Operating Margin N/A
Net Margin N/A
Country US
Market Cap 287.1B USD
Operating Margin
29%
Net Margin
11%
Country US
Market Cap 167.6B USD
Operating Margin
24%
Net Margin
13%
Country US
Market Cap 113.1B USD
Operating Margin
41%
Net Margin
39%
Country US
Market Cap 109B USD
Operating Margin
30%
Net Margin
29%
Country AU
Market Cap 134.1B AUD
Operating Margin
26%
Net Margin
17%
Country US
Market Cap 83.4B USD
Operating Margin
32%
Net Margin
2%
Country US
Market Cap 54.2B USD
Operating Margin
-100%
Net Margin
-116%
Country US
Market Cap 43.1B USD
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 32.9B USD
Operating Margin
22%
Net Margin
12%
Country KR
Market Cap 38.6T KRW
Operating Margin
30%
Net Margin
25%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Madrigal Pharmaceuticals Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
4.8B USD
-89%
-63%
-76%
12 095%
US
Abbvie Inc
NYSE:ABBV
287.1B USD
56%
4%
15%
13%
US
Amgen Inc
NASDAQ:AMGN
167.6B USD
73%
4%
10%
9%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.1B USD
24%
19%
23%
33%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
109B USD
15%
12%
14%
17%
AU
CSL Ltd
ASX:CSL
134.1B AUD
15%
7%
11%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
83.4B USD
3%
1%
18%
7%
US
Moderna Inc
NASDAQ:MRNA
54.2B USD
-38%
-29%
-29%
-56%
US
Seagen Inc
NASDAQ:SGEN
43.1B USD
-28%
-21%
-27%
-39%
US
Biogen Inc
NASDAQ:BIIB
32.9B USD
8%
5%
9%
8%
KR
Celltrion Inc
KRX:068270
38.6T KRW
5%
4%
6%
4%
Country US
Market Cap 4.8B USD
ROE
-89%
ROA
-63%
ROCE
-76%
ROIC
12 095%
Country US
Market Cap 287.1B USD
ROE
56%
ROA
4%
ROCE
15%
ROIC
13%
Country US
Market Cap 167.6B USD
ROE
73%
ROA
4%
ROCE
10%
ROIC
9%
Country US
Market Cap 113.1B USD
ROE
24%
ROA
19%
ROCE
23%
ROIC
33%
Country US
Market Cap 109B USD
ROE
15%
ROA
12%
ROCE
14%
ROIC
17%
Country AU
Market Cap 134.1B AUD
ROE
15%
ROA
7%
ROCE
11%
ROIC
9%
Country US
Market Cap 83.4B USD
ROE
3%
ROA
1%
ROCE
18%
ROIC
7%
Country US
Market Cap 54.2B USD
ROE
-38%
ROA
-29%
ROCE
-29%
ROIC
-56%
Country US
Market Cap 43.1B USD
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 32.9B USD
ROE
8%
ROA
5%
ROCE
9%
ROIC
8%
Country KR
Market Cap 38.6T KRW
ROE
5%
ROA
4%
ROCE
6%
ROIC
4%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More